Asked by: Sharon Hodgson (Labour - Washington and Gateshead South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, for what reason (a) Valproate redress and (b) interim payments are delayed.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is carefully considering the valuable work done by the Patient Safety Commissioner and the resulting Hughes Report, which set out options for redress for those harmed by valproate and pelvic mesh. This is a complex area of work, involving several Government departments. We will be providing an update to the Patient Safety Commissioner’s report at the earliest opportunity.
Asked by: Sharon Hodgson (Labour - Washington and Gateshead South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of controls on stocking (a) palliative care medicines and (b) controlled drugs on the (i) adequacy of access to medication for patients in care homes and (ii) levels of wastage.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Under the Enhanced health in care homes framework, every care home must be aligned to a primary care network (PCN) and must have established protocols between the PCN, the care home, and system partners, such as local general practices and pharmacies, for information sharing, shared care planning, use of shared care records, and clear clinical governance.
Pharmacies are expected to maintain a reasonable stock holding to meet their legal obligations to dispense all prescriptions, including to patients in care homes, with reasonable promptness, recognising that it is not feasible for a pharmacy to maintain stock of every medicine. The Pharmacy Quality Scheme rewards community pharmacy contractors that deliver quality criteria, one of which is the Palliative and End of Life Care scheme. Participating pharmacy contractors must declare if they intend to routinely stock 16 critical end of life medicines, including controlled drugs such as morphine and midazolam and/or parenteral haloperidol, and must have an action plan in place to support local access. This enables palliative medicines to be quickly sourced when prescribed.
Most care homes with nursing can hold stocks of controlled drugs and will not require a licence to access medicines containing controlled drugs for patients who need them. This is because care homes run by public authorities or charities are exempt from the need for a Home Office controlled drug licence. Care homes without nursing cannot store controlled drugs unless they are prescribed for individual residents.
The Government seeks to have a coordinated approach to prevent wastage as much as possible, to improve inefficiencies and reduce costs for the taxpayer. PCNs are required to ensure that Structured Medication Reviews (SMRs) for high-risk cohorts, such as care home patients, are implemented. SMRs are an evidence based comprehensive review of a person’s medication, their views, concerns, and safety. The use of SMRs can reduce harmful polypharmacy and medicine wastage.
Asked by: Sharon Hodgson (Labour - Washington and Gateshead South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the adequacy of access to (a) palliative care medicines and (b) controlled drugs for patients in care homes.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Under the Enhanced health in care homes framework, every care home must be aligned to a primary care network (PCN) and must have established protocols between the PCN, the care home, and system partners, such as local general practices and pharmacies, for information sharing, shared care planning, use of shared care records, and clear clinical governance.
Pharmacies are expected to maintain a reasonable stock holding to meet their legal obligations to dispense all prescriptions, including to patients in care homes, with reasonable promptness, recognising that it is not feasible for a pharmacy to maintain stock of every medicine. The Pharmacy Quality Scheme rewards community pharmacy contractors that deliver quality criteria, one of which is the Palliative and End of Life Care scheme. Participating pharmacy contractors must declare if they intend to routinely stock 16 critical end of life medicines, including controlled drugs such as morphine and midazolam and/or parenteral haloperidol, and must have an action plan in place to support local access. This enables palliative medicines to be quickly sourced when prescribed.
Most care homes with nursing can hold stocks of controlled drugs and will not require a licence to access medicines containing controlled drugs for patients who need them. This is because care homes run by public authorities or charities are exempt from the need for a Home Office controlled drug licence. Care homes without nursing cannot store controlled drugs unless they are prescribed for individual residents.
The Government seeks to have a coordinated approach to prevent wastage as much as possible, to improve inefficiencies and reduce costs for the taxpayer. PCNs are required to ensure that Structured Medication Reviews (SMRs) for high-risk cohorts, such as care home patients, are implemented. SMRs are an evidence based comprehensive review of a person’s medication, their views, concerns, and safety. The use of SMRs can reduce harmful polypharmacy and medicine wastage.
Asked by: Sharon Hodgson (Labour - Washington and Gateshead South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of misdiagnosis of women’s health symptoms on levels of diagnosis of ovarian cancer in (a) all women and (b) women under the age of 50.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to improving the diagnosis, treatment, and ongoing care of gynaecological conditions, including ovarian cancer. NHS England has taken urgent action to address gynaecology waiting lists through the Elective Recovery Plan, including support for innovative care models that bring services closer to patients, and the piloting of gynaecology pathways within community diagnostic centres.
As a first step towards improving the diagnosis of ovarian cancer and reducing misdiagnosis, the National Health Service is now delivering an extra 40,000 operations, scans, and appointments each week. The NHS is also improving pathways to get people diagnosed once they are referred, including non-specific symptom pathways for patients who do not fit clearly into a single urgent cancer referral pathway. Combined, these interventions will help ensure early diagnosis and faster treatment, including for women with ovarian cancer, with further actions to be outlined in the forthcoming National Cancer Plan.
The most recent data available from the National Disease Registration Service shows that in England in 2022, 3,151 people were diagnosed with ovarian cancer at stages 3 & 4, which is classed as advanced.
Asked by: Sharon Hodgson (Labour - Washington and Gateshead South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of the removal of the target to increase the percentage of cancers diagnosed at stages 1 and 2 from the NHS Priorities and Operational Planning Guidance on women with ovarian cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to improving the diagnosis, treatment, and ongoing care of gynaecological conditions, including ovarian cancer. NHS England has taken urgent action to address gynaecology waiting lists through the Elective Recovery Plan, including support for innovative care models that bring services closer to patients, and the piloting of gynaecology pathways within community diagnostic centres.
As a first step towards improving the diagnosis of ovarian cancer and reducing misdiagnosis, the National Health Service is now delivering an extra 40,000 operations, scans, and appointments each week. The NHS is also improving pathways to get people diagnosed once they are referred, including non-specific symptom pathways for patients who do not fit clearly into a single urgent cancer referral pathway. Combined, these interventions will help ensure early diagnosis and faster treatment, including for women with ovarian cancer, with further actions to be outlined in the forthcoming National Cancer Plan.
The most recent data available from the National Disease Registration Service shows that in England in 2022, 3,151 people were diagnosed with ovarian cancer at stages 3 & 4, which is classed as advanced.
Asked by: Sharon Hodgson (Labour - Washington and Gateshead South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate his Department has made on the number of patients diagnosed with ovarian cancer at an advanced stage.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to improving the diagnosis, treatment, and ongoing care of gynaecological conditions, including ovarian cancer. NHS England has taken urgent action to address gynaecology waiting lists through the Elective Recovery Plan, including support for innovative care models that bring services closer to patients, and the piloting of gynaecology pathways within community diagnostic centres.
As a first step towards improving the diagnosis of ovarian cancer and reducing misdiagnosis, the National Health Service is now delivering an extra 40,000 operations, scans, and appointments each week. The NHS is also improving pathways to get people diagnosed once they are referred, including non-specific symptom pathways for patients who do not fit clearly into a single urgent cancer referral pathway. Combined, these interventions will help ensure early diagnosis and faster treatment, including for women with ovarian cancer, with further actions to be outlined in the forthcoming National Cancer Plan.
The most recent data available from the National Disease Registration Service shows that in England in 2022, 3,151 people were diagnosed with ovarian cancer at stages 3 & 4, which is classed as advanced.
Asked by: Sharon Hodgson (Labour - Washington and Gateshead South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential merits of expanding the Family Nurse Partnership to include more than the existing 44 local authorities.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Family Nurse Partnership Programme (FNP) is the Department’s current service for the most vulnerable first-time parents, for example, teenagers, care leavers, those known to the care system, or those who would otherwise have extremely poor clinical outcomes, affecting both themselves and their children. The FNP has been shown to improve vulnerable children’s development, school readiness and early educational attainment.
Provision of the FNP is currently a choice for local authorities. The programme is currently available in 45 local authorities. Local authorities have a statutory duty for commissioning public health services for children and young people aged between zero and 19 years old. The Public Health Grant, from which various programmes for children and young people are funded, including FNP, has been uplifted for 2025/26 by 5.4%, a percentage equalling almost £200 million.
Asked by: Sharon Hodgson (Labour - Washington and Gateshead South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many hernia mesh surgeries have taken place in each of the last 20 years; and what steps his Department is taking to ensure that patients are informed of the risks of mesh complications.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The following table shows the count of Finished Consultant Episodes (FCEs) where there was any procedure for 'hernia mesh surgeries', recorded for the years 2004/05 to 2023/24, in English National Health Service hospitals and English NHS commissioned activity in the independent sector:
Year | FCEs |
2004/05 | 77,849 |
2005/06 | 79,748 |
2006/07 | 83,789 |
2007/08 | 89,063 |
2008/09 | 87,401 |
2009/10 | 85,519 |
2010/11 | 85,697 |
2011/12 | 90,593 |
2012/13 | 89,676 |
2013/14 | 95,608 |
2014/15 | 95,854 |
2015/16 | 92,147 |
2016/17 | 93,887 |
2017/18 | 89,016 |
2018/19 | 89,951 |
2019/20 | 81,780 |
2020/21 | 39,034 |
2021/22 | 70,884 |
2022/23 | 78,917 |
2023/24 | 83,045 |
Source: Hospital Episode Statistics, NHS England.
Clinicians are expected to inform patients about risks associated with recommended treatments, including reasonable alternatives, to enable informed consent and a balanced patient decision.
Asked by: Sharon Hodgson (Labour - Washington and Gateshead South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to NCEPOD's report entitled Joint Care? A review of the quality of care provided to children and young adults with juvenile idiopathic arthritis, published on 13 February 2025, whether he will take steps to implement the recommendations of that report as they relate to recognition of juvenile idiopathic arthritis by healthcare professionals.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department has not yet considered the recommendations of the report published by the National Confidential Enquiry into Patient Outcome and Death on 13 February 2025, Joint Care? A review of the quality of care provided to children and young adults with juvenile idiopathic arthritis.
NHS England Specialised Commissioning has a Clinical Reference Group for specialised paediatric rheumatology, which has produced a service specification for these services. This service specification names juvenile idiopathic arthritis as one of the conditions that should be managed by a specialist paediatric rheumatology team. The service specification also sets out that specialised paediatric rheumatology teams will provide transitional care to facilitate transfer and ongoing care in adult rheumatology. Transitional care planning will involve paediatric rheumatology teams, adult rheumatology teams and local hospitals under a shared care arrangement. Specialised paediatric rheumatology services are expected to be commissioned in line with this service specification.
In the NHS Long Term Plan, NHS England committed to delivering a service model for people aged between zero and 25 years old to improve young people’s experience and health outcomes. To aid implementation of this model, the Children and Young People’s Transformation Programme collaborated with key partners to develop national guidance on how the National Health Service can better support young people transfer into adolescent and adult services. The guidance is due to be published shortly and will be hosted on the NHS England website.
The policy aligns with existing National Institute for Health and Care Excellence (NICE) guidelines and outlines the principles and steps of a service model for people aged between zero and 25 years old, along with best practice examples from across the country.
NICE’s published guidance on the transition from children’s to adult services for young people includes recommendations on transition planning, support before and after transfer and the development of transition infrastructure. This guidance is available at the following link:
https://www.nice.org.uk/guidance/ng43
Asked by: Sharon Hodgson (Labour - Washington and Gateshead South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to support older children with arthritis as they transition to adult health and care services.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department has not yet considered the recommendations of the report published by the National Confidential Enquiry into Patient Outcome and Death on 13 February 2025, Joint Care? A review of the quality of care provided to children and young adults with juvenile idiopathic arthritis.
NHS England Specialised Commissioning has a Clinical Reference Group for specialised paediatric rheumatology, which has produced a service specification for these services. This service specification names juvenile idiopathic arthritis as one of the conditions that should be managed by a specialist paediatric rheumatology team. The service specification also sets out that specialised paediatric rheumatology teams will provide transitional care to facilitate transfer and ongoing care in adult rheumatology. Transitional care planning will involve paediatric rheumatology teams, adult rheumatology teams and local hospitals under a shared care arrangement. Specialised paediatric rheumatology services are expected to be commissioned in line with this service specification.
In the NHS Long Term Plan, NHS England committed to delivering a service model for people aged between zero and 25 years old to improve young people’s experience and health outcomes. To aid implementation of this model, the Children and Young People’s Transformation Programme collaborated with key partners to develop national guidance on how the National Health Service can better support young people transfer into adolescent and adult services. The guidance is due to be published shortly and will be hosted on the NHS England website.
The policy aligns with existing National Institute for Health and Care Excellence (NICE) guidelines and outlines the principles and steps of a service model for people aged between zero and 25 years old, along with best practice examples from across the country.
NICE’s published guidance on the transition from children’s to adult services for young people includes recommendations on transition planning, support before and after transfer and the development of transition infrastructure. This guidance is available at the following link:
https://www.nice.org.uk/guidance/ng43